YUVA-GT-F801 / SZGIMI - LARVOL DELTA

Lentiviral FVIII Gene Therapy (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2028 ➔ Dec 2028 | Trial primary completion date: May 2027 ➔ May 2028

Trial completion date • Trial primary completion date • Gene Therapies • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Lentiviral FVIII Gene Therapy (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Unknown status ➔ Recruiting | Trial completion date: Jun 2022 ➔ Jun 2028 | Trial primary completion date: May 2022 ➔ May 2027

Enrollment open • Trial completion date • Trial primary completion date • Gene Therapies • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Lentiviral FVIII Gene Therapy (clinicaltrials.gov) - P1; N=10; Not yet recruiting; Sponsor: Shenzhen Geno-Immune Medical Institute; Phase classification: P1/2 ➔ P1

Phase classification